At AHA #ScientificSessions26#, Amgen presented data highlighting the cost effectiveness of intensive LDL-C lowering, building on years of established clinical evidence.
Read the press release:
$AMGN
At AHA #ScientificSessions26#, Amgen is adding to its extensive base of cardiovascular evidence, with new research exploring LDL-C management, long-term outcomes and the economic considerations of care.
Explore our abstracts ⬇️